parkinson diseases
DESCRIPTION
TRANSCRIPT
PARKINSON’S DISEASE
PRESENTED BY-
NAVEEN KADIAN
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY
K.L.E’S COLLEGE OF PHARMACY
BELGAUM-10
CONTENTS
• Introduction• Epidemiology of PD• Causes of Parkinsonism• Risk factors of PD• Clinical features of PD• Treatment• Reference
Definition• Neurodegenerative disease is a condition which affects
brain function. Neurodegenerative diseases result from deterioration of neurons.
• They are divided into two groups: – conditions causing problems with movements – conditions affecting memory and conditions related to
dementia.
– Examples:• Alzheimer’s • Parkinson’s• Huntington’s• Creutzfeldt-Jakob disease• Multiple Sclerosis• Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's
Disease)
Risk Factors• Known
– Certain genetic polymorphisms
– Increasing age
PossibleGenderPoor educationEndocrine conditionsOxidative stressInflammationStrokeHypertensionDiabetesHead traumaDepressionInfectionTumorsVitamin deficienciesImmune and metabolic conditionsChemical exposureSmoking??
PARKINSON`S DISEASE is movement disorder of unknown etiology due to degeneration of neurons in the nigrostrial dopamine system.
History:First described in 1817 by an English physician, James Parkinson, in “An Essay on the Shaking Palsy.”
The famous French neurologist, Charcot, further described the syndrome in the late 1800s.
Epidemiology of PD
The most common movement disorder affecting 1-2 % of the general population over the age of 65 years.
The second most common neurodegenerative disorder after Alzheimer´s disease (AD).
Causes of Parkinsonism• Impaired release of dopamine- Idiopathic
parkinsonism.
• Drug depleting dopamine store-reserpine, tetrabenzine.
• Toxin damaging dopaminergic neuron.
• Viral infection- Encephalitis ,Japanese encephalitis
• Trauma-repeated head injury[punch drunk syndrome]
• Miscellaneus-wilson disease,huntingtion,s disease
Dopamine pathways in human brain
Dopamine synthesis
Risk factors of PD Age - the most important risk factor Positive family history Male gender Environmental exposure: Herbicide and pesticide
exposure, metals (manganese, iron), well water, farming, rural residence, wood pulp mills; and steel alloy industries
Race Life experiences (trauma, emotional stress, personality
traits such as shyness and depressiveness)? An inverse correlation between cigarette smoking and
caffeine intake in case-control studies.
Clinical features of PD
• Three cardinal symptoms:
® resting tremor
® bradykinesia (generalized slowness of
movements)
® muscle rigidity
CLINICAL FEATURE• TREMORS(4-6hz): • tremors[pill rolling] at rest, decreases on action.
Usually first in finger/thumb.• Coarse flexion/extension of finger[pill rolling &
drum beating]• RIGIDITY- • Cog wheel type especially in upper limb
{stiffness in all direction of movement}.• Plastic type {lead type} mostly appreciated in
legs. In trunk rigidity manifest by flexed& stooped posture
Hypokinesis• Charactrized by poverty & slowness of
movement. Slowness in initiating movement. Handwriting micrographia.
• GAIT-patient walk with short step , with a tendency to run{as they are catching their own centre of gravity}-festinating gait
• General-expressionless face with staring look with infrequent blinking. Monotonus speech. Dementia & Depression in advance stage
Drugs used to treat Parkinson’s Disease
TREATMENT• Anticholinergic drug- to relieve tremors.• Dopamine agonist- bromocriptine&
pergolide.• Amantadine-potentiate release of
dopamine.• Selegeline : early stage, neuroprotective, delay
neuronal degeneration.
• Levodopa & carbidopa
Therapy of PD: levodopa
Late 1950s: L-dihydroxyphenylalanine (L-DOPA; levodopa), a precursor of DA that crosses the blood-brain barrier, could restore brain DA levels and motor functions in animals treated with catecholamine depleting drug (reserpine).
First treatment attempts in PD patients with levodopa resulted in dramatic but short-term improvements; took years before it become an established and succesfull treatment.
Still today, levodopa cornerstone of PD treatment; virtually all the patients benefit.
Therapy of PD: limitations of levodopa
Efficacy tends to decrease as the disease progresses.
Chronic treatment associated with adverse events (motor fluctuations, dyskinesias and neuropsychiatric problems).
Inhibition of peripheral COMT by entacapone increases the amount of L-DOPA and dopamine in the brain and improves the alleviation of PD symptoms.
Therapy of PD: limitations of levodopa
Does not prevent the continuous degeneration of nerve cells in the subtantia nigra, the treatment being therefore symptomatic.
Therapy of PD: Other treatmentsDA receptor agonists:
Bromocriptine Pergolide
ropinirolecabergoline
Anticholinergics:
Amantadine
AntiHistamines:
Diphenhydramine Orphenadrine
Selegiline
Antidepressant
Miscellanous:
imipraminenortriptyline
Benzotropineprocyclidine
References BURGER’S Medicinal Chemistry & Drug discovery,6th
Edn,vol-1, Wiley-interscience publication CORWIN HANSCH, Comprehensive Medicinal
Chemistry,vol –IV 2008,Pregamon press Principles of Medicinal Chemistry by William O.Foye Medicinal Pharmacology by K.D Triphati. http:// www.cpharm.ucsf.edu/ kuntz/doct.html http:// www.bmm.icnet.uk/ ftdock/ftdoc.html www. Wikepedia.com www. Google.com www. Ipasp . com
THANK
YOU